- 专利标题: Macrocyclic ghrelin receptor modulators and methods of using the same
-
申请号: US15178303申请日: 2016-06-09
-
公开(公告)号: US09949949B2公开(公告)日: 2018-04-24
- 发明人: Hamid Hoveyda , Graeme Fraser , Kamel Benakli , Eric Marsault , Mark L. Peterson
- 申请人: OCERA THERAPEUTICS, INC.
- 申请人地址: US CA Palo Alto
- 专利权人: Ocera Therapeutics, Inc.
- 当前专利权人: Ocera Therapeutics, Inc.
- 当前专利权人地址: US CA Palo Alto
- 代理机构: Ward & Smith, P.A.
- 主分类号: C07K5/12
- IPC分类号: C07K5/12 ; A61K31/395 ; C07D273/00 ; C07C271/16 ; C07C215/42 ; C07C215/54 ; C07D413/06 ; C07D498/04 ; C07D498/16
摘要:
The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone sceretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.